Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Video Centre
Jonathon Morrissey, Superintendent Pharmacist speaks about Herpes Zoster vaccination in pharmacy
Shingrix Abbreviated Prescribing Information
Burden of Disease
Chapter 1 of 5
Who is at risk of shingles?
Chapter 2 of 5
Treatment of shingles
Chapter 3 of 5
How can you protect your patients against shingles?
Chapter 4 of 5
How can you confidently recommend SHINGRIX to your patients at risk?
Chapter 5 of 5
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
PM-IE-SGX-WCNT-260001 Date of Preparation: March 2026
Importance of Adult
Immunisation
Role of Pharmacist - Adult Immunisation
Effective Communication - Adult Immunisation
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
SHINGRIX is owned by or licensed to the GSK group of companies.
©2026 GSK group of companies or its licensor.
GlaxoSmithKline Biologicals S.A. Rixensart, Belgium.
PM-IE-SGX-WCNT-240004
Date of preparation: April 2026
